Viking Therapeutics (1VT) Ownership - Who Owns Viking Therapeutics?
Viking Therapeutics (1VT) Ownership Overview
- 2.71% Insiders
- 17.04% Mutual Funds
- 0.88% Other Institutional Investors
- 13.45% ETFs
- 65.93% Public Companies and Individual Investors
The ownership structure of Viking Therapeutics (DE:1VT) stock is a mix of institutional, retail, and individual investors. Approximately 31.36% of the company’s stock is owned by Institutional Investors, 2.71% is owned by Insiders, and 65.93% is owned by Public Companies and Individual Investors.
The ownership structure of Viking Therapeutics (DE:1VT) stock is a mix of institutional, retail, and individual investors. Approximately 31.36% of the company’s stock is owned by Institutional Investors, 2.71% is owned by Insiders, and 65.93% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
| Date | Name | Activity | Value |
|---|---|---|---|
| Jul 28, 2026 | Greg Zante | $710,133 | |
| Jul 28, 2026 | Marianna Mancini | $609,541 | |
| Jul 28, 2026 | Brian Lian | $4,947,101 | |
| Mar 09, 2026 | Neil William Aubuchon | $149,913 |
Recent Hedge Fund Trading Activity
| Date | Firm | Activity | Value |
|---|---|---|---|
| Dec 31, 2025 | Goalvest Advisory Llc | €5,277 | |
| Dec 31, 2025 | Soros Fund Mangment Llc | €3,166,200 | |
| Dec 31, 2025 | Bridgewater Associates, Lp | €3,646,723 | |
| Dec 31, 2025 | Woodline Partners Lp | €10,625,485 |
Top Shareholders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Vanguard | 9,893,310 | Institution | 7.76% | 265,556,227 |
| Vanguard Index Funds | 8,820,049 | Institution | 6.92% | 236,747,755 |
| BlackRock, Inc. | 6,189,649 | Institution | 4.85% | 166,142,558 |
| Spdr | 3,638,372 | Institution | 2.85% | 97,661,181 |
| Brian Lian | 2,572,441 | Insider | 2.02% | 69,049,461 |
| Ishares | 1,704,212 | Institution | 1.34% | 45,744,459 |
| American Century Mutual Funds, Inc. | 1,555,224 | Institution | 1.22% | 41,745,323 |
| Fidelity Concord Street Trust | 1,270,029 | Institution | 1.00% | 34,090,118 |
| Fidelity Advisor Series I | 1,259,984 | Institution | 0.99% | 33,820,491 |
| Delaware Group Equity Funds Iv | 996,435 | Institution | 0.78% | 26,746,308 |
Top Mutual Fund Holders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Vanguard Index Funds | 8,820,049 | Institution | 6.92% | 236,747,755 |
| American Century Mutual Funds, Inc. | 1,555,224 | Institution | 1.22% | 41,745,323 |
| Fidelity Concord Street Trust | 1,270,029 | Institution | 1.00% | 34,090,118 |
| Fidelity Advisor Series I | 1,259,984 | Institution | 0.99% | 33,820,491 |
| Delaware Group Equity Funds Iv | 996,435 | Institution | 0.78% | 26,746,308 |
| Fidelity Select Portfolios | 959,157 | Institution | 0.75% | 25,745,692 |
| Fidelity Advisor Series Vii | 730,187 | Institution | 0.57% | 19,599,679 |
| Fidelity Securities Fund | 641,896 | Institution | 0.50% | 17,229,772 |
| Fidelity Salem Street Trust | 567,827 | Institution | 0.45% | 15,241,612 |
| Fidelity Capital Trust | 537,400 | Institution | 0.42% | 14,424,891 |
FAQ
Who Owns Viking Therapeutics (DE:1VT)?
According to the latest TipRanks data, approximately 31.36% of the company's stock is held by institutional investors, 2.71% is held by insiders, and 65.93% is held by public companies and individual investors.
What percentage of Viking Therapeutics (DE:1VT) stock is held by institutional investors?
According to the latest TipRanks data, approximately 31.36% of Viking Therapeutics (DE:1VT) stock is held by institutional investors: 17.04% by mutual funds, 13.45% by ETFs and 0.88% by other institutional investors.
What percentage of Viking Therapeutics (DE:1VT) stock is held by retail investors?
According to the latest TipRanks data, approximately 65.93% of Viking Therapeutics (DE:1VT) stock is held by public companies and individual investors.
Who owns the most shares of Viking Therapeutics (DE:1VT)?
Vanguard owns the most shares of Viking Therapeutics (DE:1VT).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
